Melanoma: all 3,073 studies

Page 29 of 31. Open to participants first (529), then studies with results posted, then the rest; newest registration first within each.

• A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic MelanomaCompletedNCT00223899Phase 1
• PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial)CompletedNCT00221702Phase 3
• Intralesional PV-10 Chemoablation of Metastatic MelanomaCompletedNCT00219843Phase 1
• Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By SurgeryCompletedNCT00217542Phase 1
• Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma PatientsCompletedNCT00204607Phase 1/2
• Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28CompletedNCT00204594Phase 1/2
• Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma MetastasesCompletedNCT00204581Phase 2
• Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIBCompletedNCT00204529Phase 3
• Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted AntigensCompletedNCT00204516Phase 1/2
• Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic MelanomaCompletedNCT00203879Phase 2
• A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of MelanomaCompletedNCT00203008
• Tumor Infiltrating Lymphocytes Adjuvant Therapy of MelanomaCompletedNCT00200577Phase 3
• A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced MelanomaTerminatedNCT00199342Phase 1/2
• Dendritic Cell Based Therapy of Malignant MelanomaCompletedNCT00197912Phase 1/2
• Use of 852A in Metastatic Cutaneous Melanoma.CompletedNCT00189332Phase 2
• Ultrasound Biomicroscopy - ApoptosisCompletedNCT00188370Phase 2
• Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic MelanomaCompletedNCT00185302Phase 2
• Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With MelanomaTerminatedNCT00184067Phase 2
• Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])CompletedNCT00179764Not applicable
• Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic ChemotherapyCompletedNCT00179608Phase 1
• Study of Metastatic Ocular MelanomaStatus unknownNCT00168870Phase 2
• Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma PatientsSuspendedNCT00160992Phase 1
• Multiepitope Peptide Vaccination in MelanomaStatus unknownNCT00153569Phase 2
• MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.TerminatedNCT00147550Phase 1/2
• Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic MelanomaCompletedNCT00139360Phase 2
• Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic MelanomaTerminatedNCT00138229Phase 2
• A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral BudesonideCompletedNCT00135408Phase 2
• An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing RadiationCompletedNCT00132704
• Vaccine Therapy in Treating Patients With Malignant MelanomaStatus unknownNCT00128583Phase 2
• Vaccine Therapy in Treating Patients With Stage IV MelanomaStatus unknownNCT00126685Phase 1/2
• Vaccination of Patients With Stage IV Melanoma With Dendritic CellsCompletedNCT00125749Phase 1/2
• Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma VaccineCompletedNCT00124124Phase 1
• A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic MelanomaCompletedNCT00121680Phase 1
• Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By SurgeryCompletedNCT00119249Phase 2
• Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV MelanomaCompletedNCT00118313Phase 1
• Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic MelanomaCompletedNCT00116597Phase 1/2
• Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit MelanomaStatus unknownNCT00116363Phase 2
• Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid TumorsCompletedNCT00112476Phase 1
• Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma PatientsCompletedNCT00112229Phase 1
• Immunotherapy of Melanoma PatientsCompletedNCT00112216Phase 1
• Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant MelanomaCompletedNCT00111696Phase 1
• Pain Relief - Tramadol Versus IbuprofenStatus unknownNCT00111046Phase 1/2
• Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye MelanomaTerminatedNCT00110123Phase 3
• Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced MelanomaCompletedNCT00109863Phase 2
• Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical CancerStatus unknownNCT00108875Phase 1/2
• Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic MelanomaCompletedNCT00107718Phase 2
• Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV MelanomaCompletedNCT00107159Phase 2
• S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By SurgeryCompletedNCT00104988Phase 2
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant MelanomaCompletedNCT00104897Phase 2
• Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV MelanomaCompletedNCT00104845Phase 1
• Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With ChemotherapyCompletedNCT00099970Phase 2
• Everolimus in Treating Patients With Stage IV MelanomaCompletedNCT00098553Phase 2
• SB-715992 in Treating Patients With Metastatic or Recurrent Malignant MelanomaCompletedNCT00095953Phase 2
• Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney CancerCompletedNCT00095108Phase 1
• Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced CancerWithdrawnNCT00093678Not applicable
• Trial of ABI-007 in Previously Treated Patients With Metastatic MelanomaCompletedNCT00093119Phase 2
• Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin LesionsCompletedNCT00091689Phase 1
• Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic MelanomaCompletedNCT00091338Phase 1
• Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic MelanomaCompletedNCT00091143Phase 1
• Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic MelanomaCompletedNCT00091104Phase 1
• CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With SurgeryCompletedNCT00090896Phase 1
• Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00089362Phase 1
• Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV MelanomaCompletedNCT00089219Phase 1/2
• Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By SurgeryCompletedNCT00089206Phase 2
• Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV MelanomaCompletedNCT00089193Phase 2
• Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for MelanomaCompletedNCT00089063Phase 2
• Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant MelanomaTerminatedNCT00087776Phase 3
• A Pilot Study of Pivanex in Patients With Malignant MelanomaTerminatedNCT00087477Phase 1/2
• Tanespimycin in Treating Patients With Stage III-IV MelanomaTerminatedNCT00087386Phase 2
• Vaccine Therapy in Treating Patients With Metastatic MelanomaTerminatedNCT00087373Phase 2
• Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With SurgeryStatus unknownNCT00086866Phase 2
• CP-675,206 In Patients With Advanced MelanomaCompletedNCT00086489Phase 2
• Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV MelanomaWithdrawnNCT00085579Phase 2
• Vaccine Therapy in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00085488Phase 1
• Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic MelanomaCompletedNCT00085462Phase 1
• Vaccine Therapy in Treating Patients With Stage III or Stage IV MelanomaStatus unknownNCT00085397Phase 2
• Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular MelanomaCompletedNCT00085306Phase 2
• Vaccine Therapy in Treating Patients With Stage IIC-IV MelanomaCompletedNCT00085189Phase 2
• Boron Neutron Capture Therapy Using Boronophenylalanine-Fructose Complex in Treating Patients With Metastatic MelanomaTerminatedNCT00085059Phase 2
• STA-4783/Paclitaxel or Paclitaxel Alone in MelanomaCompletedNCT00084214Phase 1/2
• Study of Talabostat and Cisplatin in Advanced MelanomaCompletedNCT00083252Phase 2
• Study of Talabostat in Advanced MelanomaCompletedNCT00083239Phase 2
• Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney CancerCompletedNCT00082914Phase 2
• Cilengitide in Treating Patients With Unresectable or Metastatic MelanomaTerminatedNCT00082875Phase 2
• ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic MelanomaCompletedNCT00081042Phase 2
• Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced MelanomaCompletedNCT00080353Phase 2
• Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00079144Phase 2
• Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV MelanomaCompletedNCT00077532Phase 2
• Vaccine Therapy in Treating Patients With Stage IV Cutaneous MelanomaCompletedNCT00074230Phase 1/2
• PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV MelanomaCompletedNCT00073892Phase 1/2
• Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV MelanomaCompletedNCT00072345Phase 2
• Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to MelanomaCompletedNCT00072163Phase 2
• Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV MelanomaCompletedNCT00072124Phase 3
• Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic MelanomaCompletedNCT00072085Phase 2
• CPG 7909 Injection in MelanomaCompletedNCT00070642Phase 2
• Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301Status unknownNCT00070343Not applicable
• Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous SystemTerminatedNCT00068666Phase 2
• Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic MelanomaCompletedNCT00068211Phase 2
• Study of PI-88 in Patients With Advanced MelanomaCompletedNCT00068172Phase 1/2
• Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic MelanomaCompletedNCT00066196Phase 2

← Melanoma overview